NDA 019281 · Pfizer
Cyklokapron
Tranexamic Acid · Injection · Antifibrinolytic Agent
OrphanLast checked: Nov 19, 2026Latest source record: Aug 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Dec 30, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
728
175 Phase 3, 72 recruiting
FAERS reports
9,075
8,437 serious, 1,336 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered via the neuraxial route [see Warnings and Precautions (5.1) ]. WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION See full prescribing information for complete boxed warning. CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered intrathecally via the neuraxial route. ( 5.1 )
What it is approved for
From the label in effect Sep 3, 2025.
CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. ( 1 )
Mechanism: Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure. The antifibrinolytic effects of tranexamic acid are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains 4 to 5 lysine binding sites with low affinity for tranexamic acid (Kd = 750 μmol/L) and 1 with high...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 1986 Original approval · Type 3 - New Dosage Form
1 products under this application
- CYKLOKAPRON · TRANEXAMIC ACID 100MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Tranexamic Acid" as an intervention, any sponsor and status, largest first.
- Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher RiskPivotal-lookingRecruiting
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT05562609 · 40,000 participants (planned) · Start Apr 22, 2024 · Primary completion Sep 2027
Drug: Tranexamic acid · For: Postpartum Hemorrhage
Sites: Mbeya, Tanzania
- Clinical Randomisation of an Antifibrinolytic in Significant HaemorrhagePivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00375258 · 20,211 participants · Start May 2005 · Primary completion Feb 2010
Drug: Tranexamic acid; Sodium Chloride 0.9% · For: Hemorrhage
Sites: London, United Kingdom
- World Maternal Antifibrinolytic TrialPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00872469 · 20,060 participants · Start May 2009 · Primary completion Jun 2016
Drug: Tranexamic acid; Placebo [Saline] · For: Postpartum Haemorrhage
Sites: Ibadan, Nigeria
- APEX-STROKE Adaptive Platform Trial for StrokePivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07784569 · 20,000 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 30, 2029
Drug: Early Angong Niuhuang Pill Treatment; Yiqi Huayu Jiedu Mixture · For: Stroke
- World Maternal Antifibrinolytic Trial_2Pivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT03475342 · 15,068 participants · Start Aug 24, 2019 · Primary completion Sep 20, 2023
Drug: Tranexamic Acid · For: Intrapartum - Moderate and Severe Anaemia
Sites: Akure, Nigeria; Ibadan, Nigeria; Ilorin, Nigeria · 41 sites in all
- Clinical Randomisation of an Antifibrinolytic in Significant Head InjuryPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT01402882 · 12,737 participants · Start Jul 2012 · Primary completion Oct 2019
Drug: Tranexamic Acid · For: Traumatic Brain Injury
Sites: Tbilisi, Georgia
- Haemorrhage Alleviation With Tranexamic Acid- Intestinal SystemPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT01658124 · 12,009 participants · Start Jul 2013 · Primary completion Jul 19, 2019
Drug: Tranexamic Acid; Placebo · For: Gastrointestinal Bleeding
Sites: London, United Kingdom
- Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After CesareanPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT03364491 · 11,000 participants · Start Mar 15, 2018 · Primary completion Jul 24, 2021
Drug: Tranexamic Acid; Placebo · For: Obstetrical Complications; Hemorrhage; Labor and Delivery
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective662
- off label use657
- pyrexia373
- nausea351
- hypotension340
- diarrhoea319
- haemorrhage317
- vomiting310
- dyspnoea299
- pneumonia282
- febrile neutropenia267
- headache244
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 40 |
| 2006 | 41 |
| 2007 | 38 |
| 2008 | 68 |
| 2009 | 76 |
| 2010 | 158 |
| 2011 | 196 |
| 2012 | 191 |
| 2013 | 185 |
| 2014 | 197 |
| 2015 | 285 |
| 2016 | 311 |
| 2017 | 426 |
| 2018 | 485 |
| 2019 | 679 |
| 2020 | 614 |
| 2021 | 854 |
| 2022 | 872 |
| 2023 | 701 |
| 2024 | 951 |
| 2025 | 1,019 |
| 2026 | 647 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials.
Calacattawi R, Alshahrani M, Aleid M, et al. · J Dermatolog Treat 2024 · Systematic Review, Meta-Analysis
- Tranexamic acid as treatment for acute gastrointestinal bleeding: A comprehensive systematic review and meta-analysis.
Calderon Martinez E, Briceño Silva GD, Sanchez Cruz C, et al. · Indian J Gastroenterol 2025 · Meta-Analysis, Systematic Review
- Efficacy of topical tranexamic acid in epistaxis: A systematic review and meta-analysis.
Janapala RN, Tran QK, Patel J, et al. · Am J Emerg Med 2022 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review.
Kim HJ, Moon SH, Cho SH, et al. · Acta Derm Venereol 2017 · Meta-Analysis, Systematic Review
- Tranexamic Acid for Traumatic Injury in the Emergency Setting: A Systematic Review and Bias-Adjusted Meta-Analysis of Randomized Controlled Trials.
Fouche PF, Stein C, Nichols M, et al. · Ann Emerg Med 2024 · Systematic Review, Meta-Analysis
- A systematic review and meta-analysis assessing the use of tranexamic acid (TXA) in acute gastrointestinal bleeding.
O'Donnell O, Gallagher C, Davey MG, et al. · Ir J Med Sci 2024 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.